Richard Bruce Warren (R B Warren, Richard B Warren)

Scopus Author ID ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 56

Top Topics

Atopic Dermatitis

Top Venues

The British journal of dermatology

American journal of clinical dermatology

The Journal of dermatological treatment

Skin health and disease

This page only lists publications with an associated author ORCID identifier.

Publications

Neil J Korman, Richard Bruce Warren, Jerry Bagel, April W Armstrong, Melinda J Gooderham, Bruce E Strober, Diamant Thaҫi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. The Journal of dermatological treatment 35 (1) (2024)
Mark G Lebwohl, Richard Bruce Warren, Howard Sofen, Shinichi Imafuku, Carle F Paul, Jacek Cezary Szepietowski, Lynda Spelman, Thierry Passeron, Eleni Vritzali, Andrew Napoli, Renata M Kisa, Alex Buck, Subhashis Banerjee, Diamant Thaҫi, Andrew Blauvelt
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials. The British journal of dermatology 190 (5) (2024)
David Rutkowski, Rachel Scholey, John S Davies, Derek Pye, Fiona Blackhall, Richard Bruce Warren, Francisco Jimenez, Christopher Ernest Maitland Griffiths, Ralf Paus
EGFR/MEK inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege. The British journal of dermatology (2024)
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard Bruce Warren, Andreas Wollenberg, Emma Guttman-Yassky
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. American journal of clinical dermatology 25 (3) (2024)
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard Bruce Warren, Andreas Wollenberg, Emma Guttman-Yassky
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. American journal of clinical dermatology 25 (3) (2024)
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard Bruce Warren, Andreas Wollenberg, Emma Guttman-Yassky
Correction to: OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. American journal of clinical dermatology (2024)
Mark Lebwohl, Richard Bruce Warren, Howard Sofen, Shinichi Imafuku, Carle F Paul, Jacek Cezary Szepietowski, Lynda Spelman, Thierry Passeron, Eleni Vritzali, Andrew Napoli, Renata M Kisa, Alex Buck, Subhashis Banerjee, Diamant Thaҫi, Andrew Blauvelt
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials. The British journal of dermatology (2024)
Helen Alexander, Rayka Malek, David Prieto-Merino, Elizaveta Gribaleva, Manisha Baden, Paula Beattie, Sara Brown, Tim Burton, Shona Cameron, Bola Coker, Michael J Cork, Ross Hearn, John R Ingram, Alan D Irvine, Graham A Johnston, Alice Lambert, Mark Lunt, Irene Man, Louise Newell, Graham Ogg, Prakash Patel, Mandy Wan, Richard Bruce Warren, Richard Woolf, Zenas Zee Ngai Yiu, Nick Reynolds, Michael R Ardern-Jones, Carsten Flohr, null null
A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. The British journal of dermatology (2024)
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard Bruce Warren, Andreas Wollenberg, Emma Guttman-Yassky
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. American journal of clinical dermatology (2024)
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard Bruce Warren, Andreas Wollenberg, Emma Guttman-Yassky
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. American journal of clinical dermatology (2024)
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard Bruce Warren, Andreas Wollenberg, Emma Guttman-Yassky
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. American journal of clinical dermatology (2024)
Amelle Geurim Ra, Zoe Littlewood, Richard B Warren, Brian Keevil, Malcolm McTaggart, Richard Bruce Warren, James Bluett
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis. The British journal of dermatology 190 (6) (2024)
Monika Frysz, Smit Patel, Marie Oy Yee Li, Christopher E M Griffiths, Richard Bruce Warren, Darren M Ashcroft
Prevalence, incidence, mortality, and healthcare resource use for generalised pustular psoriasis, palmoplantar pustulosis, and plaque psoriasis in England: a population-based cohort study. The British journal of dermatology (2024)
Neil J Korman, Richard Bruce Warren, Jerry Bagel, April W Armstrong, Melinda J Gooderham, Bruce E Strober, Diamant Thaҫi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M Kisa, Subhashis Banerjee, Andrew Blauvelt
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. The Journal of dermatological treatment 35 (1) (2024)
Amelle Geurim Ra, Zoe Littlewood, Richard B Warren, Brian Keevil, Malcolm McTaggart, Richard Bruce Warren, James Bluett
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis. The British journal of dermatology 190 (6) (2024)
Amelle Geurim Ra, Zoe Littlewood, Richard B Warren, Brian Keevil, Malcolm McTaggart, Richard Bruce Warren, James Bluett
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis. The British journal of dermatology 190 (6) (2024)
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard Bruce Warren, Andreas Wollenberg, Emma Guttman-Yassky
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. American journal of clinical dermatology (2024)
Monika Frysz, Smit Patel, Marie Oy Yee Li, Christopher E M Griffiths, Richard Bruce Warren, Darren M Ashcroft
Prevalence, incidence, mortality, and healthcare resource use for generalised pustular psoriasis, palmoplantar pustulosis, and plaque psoriasis in England: a population-based cohort study. The British journal of dermatology (2024)
Amelle G Ra, Zoe Littlewood, Richard B Warren, Brian Keevil, Malcolm McTaggart, Richard Bruce Warren, James Bluett
The use of serum methotrexate level as an assessment of biochemical drug adherence in psoriasis. The British journal of dermatology (2024)
Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard Bruce Warren, Andreas Wollenberg, Emma Guttman-Yassky
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. American journal of clinical dermatology 25 (3) (2024)
Monika Frysz, Smit Patel, Marie Oy Yee Li, Christopher E M Griffiths, Richard Bruce Warren, Darren M Ashcroft
Prevalence, incidence, mortality, and healthcare resource use for generalised pustular psoriasis, palmoplantar pustulosis, and plaque psoriasis in England: a population-based cohort study. The British journal of dermatology (2024)
Mark Lebwohl, Richard Bruce Warren, Howard Sofen, Shinichi Imafuku, Carle F Paul, Jacek Cezary Szepietowski, Lynda Spelman, Thierry Passeron, Eleni Vritzali, Andrew Napoli, Renata M Kisa, Alex Buck, Subhashis Banerjee, Diamant Thaҫi, Andrew Blauvelt
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase 3 poetyk trials. The British journal of dermatology (2024)
David Rutkowski, Rachel Scholey, John S Davies, Derek Pye, Fiona Blackhall, Richard Bruce Warren, Francisco Jimenez, Christopher Ernest Maitland Griffiths, Ralf Paus
EGFR/MEK inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege. The British journal of dermatology (2024)
Duc Binh Phan, Anthony P Bewley, Catherine H Smith, Teena Mackenzie, Christopher E M Griffiths, Mark Lunt, Richard Bruce Warren, Zenas Zee Ngai Yiu
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: A drug utilisation study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). The British journal of dermatology (2023)
Kenneth B Gordon, Richard G Langley, Richard Bruce Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk de Cuyper, Owen Davies, Diamant Thaҫi
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled data from up to three years of treatment in randomized phase 3 trials. The British journal of dermatology (2023)
Richard G Langley, Howard Sofen, Ignacio Dei-Cas, Kristian Reich, Bardur Sigurgeirsson, Richard Bruce Warren, Carle F Paul, Jacek Cezary Szepietowski, Tsen Fang Tsai, Isabelle Hampele, Ruquan You, Pascal Charef, Charis Papavassilis
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. The British journal of dermatology 188 (2) (2023)
Oras A Alabas, Kaleigh J Mason, Zenas Zee Ngai Yiu, Philip J Hampton, Nick J Reynolds, Caroline M Owen, Anthony Bewley, Philip M Laws, Richard Bruce Warren, Mark Lunt, Catherine H Smith, Christopher E M Grifﬁths
Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR. The British journal of dermatology (2023)
Georgios Kokolakis, Richard Bruce Warren, Bruce E Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda J Gooderham, Andreas Körber, Veerle Vanvoorden, Maggie Wang, Dirk de Cuyper, Cynthia Madden, Natalie Nunez Gomez, Mark Lebwohl
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. The British journal of dermatology 188 (3) (2023)
Bruce E Strober, Yayoi Tada, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G Langley, Richard Bruce Warren, Maggie Wang, Veerle Vanvoorden, Balint Szilagyi, Valerie Ciaravino, Carle F Paul
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. The British journal of dermatology (2023)
April W Armstrong, Richard Bruce Warren, Yichen Zhong, Joe Zhuo, Allie Cichewicz, Ananth Kadambi, Daniela Rezende Junqueira, Tracy Westley, Renata Kisa, Carolin Daamen, Matthias Augustin
Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis. Dermatology and therapy (2023)
Richard Bruce Warren, Adam Reich, Andrzej Kaszuba, Waldemar Placek, Christopher E M Griffiths, Jihao Zhou, Bruce Randazzo, Paul Lizzul, Johann E Gudjonsson
Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial. The British journal of dermatology (2023)
Sarah Elyoussfi, Shraddha S Rane, Steve Eyre, Richard Bruce Warren
TYK2 as a novel therapeutic target in psoriasis. Expert review of clinical pharmacology (2023)
Richard G Langley, Howard Sofen, Ignacio Dei-Cas, Kristian Reich, Bardur Sigurgeirsson, Richard Bruce Warren, Carle F Paul, Jacek Cezary Szepietowski, Tsen Fang Tsai, Isabelle Hampele, Ruquan You, Pascal Charef, Charis Papavassilis
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. The British journal of dermatology 188 (2) (2023)
Kayleigh J Mason, Oras A Alabas, Nick Dand, Richard Bruce Warren, Nick J Reynolds, Jonathan N W N Barker, Zenas Zee Ngai Yiu, Catherine H Smith, Christopher E M Griffiths, null null
Characteristics of "Super-Responders" and "Super-Non-Responders" to First Biologic Monotherapy for Psoriasis: A Nested Case-control Study. The British journal of dermatology (2023)
Georgios Kokolakis, Richard Bruce Warren, Bruce E Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda J Gooderham, Andreas Körber, Veerle Vanvoorden, Maggie Wang, Dirk de Cuyper, Cynthia Madden, Natalie Nunez Gomez, Mark Lebwohl
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. The British journal of dermatology 188 (3) (2023)
Abhishek Abhishek, Matthew D Stevenson, Georgina Nakafero, Matthew J Grainge, Ian Evans, Oras Alabas, Tim Card, Maarten W Taal, Guruprasad P Aithal, Christopher P Fox, Christian David Mallen, Danielle A van der Windt, Richard D Riley, Richard Bruce Warren, Hywel C Williams
Discontinuation of anti-TNF-alpha treatment due to blood test abnormalities and cost-effectiveness of alternate blood monitoring strategies. The British journal of dermatology (2023)
Richard Bruce Warren, Victoria Basey, Anita Lynam, Charlotte Curtis, Michael R Ardern-Jones
The risk of venous thromboembolism in atopic dermatitis: A matched cohort analysis in UK primary care. The British journal of dermatology (2023)
Oras A Alabas, Kayleigh J Mason, Zenas Zee Ngai Yiu, Richard Bruce Warren, Nick Dand, Jonathan N Barker, Catherine H Smith, Christopher E M Grifﬁths, null null, null null
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). The British journal of dermatology (2023)
Bruce E Strober, Yayoi Tada, Ulrich Mrowietz, Mark Lebwohl, Peter Foley, Richard G Langley, Richard Bruce Warren, Maggie Wang, Veerle Vanvoorden, Balint Szilagyi, Valerie Ciaravino, Carle F Paul
Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. The British journal of dermatology (2023)
Georgia Lada, Gabriela Arredondo Hector Chinoy, Peter S Talbot, Richard Bruce Warren, C Elise Kleyn
The effect of the Covid-19 pandemic on illness perceptions of psoriasis and the role of depression: Findings from a cross-sectional study. Skin health and disease 2 (3) (2022)
Katie Bechman, Emma S Cook, Nick Dand, Zenas Zee Ngai Yiu, Teresa Tsakok, Freya Meynell, Bolaji Coker, Alexandra Vincent, Herve Bachelez, Ines Barbosa, Matthew A Brown, Francesca Capon, Claudia R Contreras, Claudia De La Cruz, Paola Di Meglio, Paolo Gisondi, Denis Jullien, Jade Kelly, Jo Lydie Wilfried Lambert, Camille Lancelot, Sinéad M Langan, Kayleigh J Mason, Helen McAteer, Lucy Moorhead, Luigi Naldi, Katherine Jones, Lluis L Puig, Phyllis I Spuls, Tiago Torres, Dominic Urmston, Amber Vesty, Richard Bruce Warren, Hoseah Waweru, John Weinman, Christopher Ernest Maitland Griffiths, Jonathan N W N Barker, Catherine H Smith, James B Galloway, Satveer K Mahil, null null
Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. The British journal of dermatology 187 (2) (2022)
Ali Al-Janabi, Amelle Geurim Ra, Zoe Littlewood, Amy Charlotte Foulkes, Hamish J A Hunter, Gabriela Arredondo Hector Chinoy, Christopher A Moriarty, Kimmie L Hyrich, Jimmy K Limdi, Zenas Zee Ngai Yiu, Christopher Ernest Maitland Griffiths, Richard Bruce Warren
The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. The British journal of dermatology (2022)
Georgia Lada, Gabriela Arredondo Hector Chinoy, Peter S Talbot, Richard Bruce Warren, C Elise Kleyn, null null
Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Skin health and disease 2 (4) (2022)
Georgios Kokolakis, Richard Bruce Warren, Bruce E Strober, Andrew Blauvelt, Luis Puig, Akimichi Morita, Melinda J Gooderham, Andreas Körber, Veerle Vanvoorden, Maggie Wang, Dirk de Cuyper, Cynthia Madden, Natalie Nunez Gomez, Mark Lebwohl
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. The British journal of dermatology (2022)
Ali Al-Janabi, Amelle Geurim Ra, Zoe Littlewood, Amy Charlotte Foulkes, Hamish J A Hunter, Gabriela Arredondo Hector Chinoy, Christopher A Moriarty, Kimmie L Hyrich, Jimmy K Limdi, Zenas Zee Ngai Yiu, Christopher Ernest Maitland Griffiths, Richard Bruce Warren
The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. The British journal of dermatology (2022)
Sophia Quirke-McFarlane, John Weinman, Emma S Cook, Zenas Zee Ngai Yiu, Nick Dand, Sinead M Langan, Katie Bechman, Teresa Tsakok, Kayleigh J Mason, Helen McAteer, Freya Meynell, Bolaji Coker, Alexandra Vincent, Dominic Urmston, Amber Vesty, Jade Kelly, Camille Lancelot, Lucy Moorhead, Ines A Barbosa, Herve Bachelez, Francesca Capon, Claudia R Contreras, Claudia De La Cruz, Paola Di Meglio, Paolo Gisondi, Denis Jullien, Jo Lambert, Luigi Naldi, Lluís Puig, Phyllis Spuls, Tiago Torres, Richard Bruce Warren, Hoseah Waweru, James B Galloway, Christopher E M Griffiths, Jonathan N Barker, Katherine Jones, Catherine H Smith, Satveer K Mahil, null null
Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. The British journal of dermatology (2022)
Craig L Leonardi, Kyoungah See, Russel T Burge, Zhuoer Sun, Ying Zhang, Lotus Mallbris, Alyssa Garrelts, Richard Bruce Warren
Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis. Advances in therapy 39 (5) (2022)
Ali Al-Janabi, Amy Charlotte Foulkes, Christopher Ernest Maitland Griffiths, Richard Bruce Warren
Paradoxical eczema in patients with psoriasis receiving biologics: a case series. Clinical and experimental dermatology 47 (6) (2022)
A David Burden, Siew Eng Choon, Alice B Gottlieb, Alexander A Navarini, Richard Bruce Warren
Clinical Disease Measures in Generalized Pustular Psoriasis. American journal of clinical dermatology 23 (Suppl 1) (2022)
Sophia Quirke-McFarlane, John Weinman, Emma S Cook, Zenas Zee Ngai Yiu, Nick Dand, Sinead M Langan, Katie Bechman, Teresa Tsakok, Kayleigh J Mason, Helen McAteer, Freya Meynell, Bolaji Coker, Alexandra Vincent, Dominic Urmston, Amber Vesty, Jade Kelly, Camille Lancelot, Lucy Moorhead, Ines A Barbosa, Herve Bachelez, Francesca Capon, Claudia R Contreras, Claudia De La Cruz, Paola Di Meglio, Paolo Gisondi, Denis Jullien, Jo Lambert, Luigi Naldi, Lluís Puig, Phyllis Spuls, Tiago Torres, Richard Bruce Warren, Hoseah Waweru, James B Galloway, Christopher E M Griffiths, Jonathan N Barker, Katherine Jones, Catherine H Smith, Satveer K Mahil, null null
Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. The British journal of dermatology (2022)
Chiedu E Ufodiama, Sarah J J Touyz, David A Fitzgerald, Hamish J A Hunter, Emma McMullen, Richard Bruce Warren, C Elise Kleyn
Remote consultations: an audit of the management of dermatology patients on biologics during the first wave of the COVID-19 pandemic. The Journal of dermatological treatment 33 (5) (2022)
Ali Al-Janabi, Z Littlewood, Christopher Ernest Maitland Griffiths, H J A Hunter, Gabriela Arredondo Hector Chinoy, C Moriarty, Zenas Zee Ngai Yiu, Richard Bruce Warren
Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. The British journal of dermatology 185 (3) (2021)
Zenas Zee Ngai Yiu, G Harding-Oredugba, Christopher Ernest Maitland Griffiths, Richard Bruce Warren, E McMullen, H J A Hunter
Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single-centre cross-sectional study. The British journal of dermatology 185 (2) (2021)
Richard Bruce Warren, Mark G Lebwohl, Howard Sofen, Vincent Piguet, Matthias Augustin, F Brock, null C Arendt, F Fierens, Andrew Blauvelt
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (12) (2021)
Ali Al-Janabi, Richard Bruce Warren
Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal. The British journal of dermatology 183 (2) (2020)
Kayleigh J Mason, S Williams, Zenas Zee Ngai Yiu, K McElhone, Darren M Ashcroft, C Elise Kleyn, Zarif K Jabbar-Lopez, C M Owen, Nick J Reynolds, Catherine H Smith, Nina Wilson, Richard Bruce Warren, Christopher Ernest Maitland Griffiths
Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. The British journal of dermatology 181 (2) (2019)